logo-loader
viewImmuPharma PLC

Immupharma steadfast in belief Lupuzor has commercial merit

Lupuzor did work well in certain patients, chiefly those who were antibody-positive

ImmuPharma PLC - Immupharma steadfast in belief Lupuzor has commercial merit

Immupharma PLC (LON:IMM) remains upbeat there are still commercial avenues open for its lupus treatment Lupuzor and talks are ongoing with regulators in the US about a new phase III trial.

Tim McCarthy, Immuphrama’s chairman, said: "With further analysis gained from our Phase III results, together with our extension study successfully meeting its endpoint confirming its safety profile, we are focused on progressing Lupuzor into a further Phase III trial."

The biotech had intended to run a managed access program for patients who request their doctor to prescribe Lupuzor, but this has now been postponed to focus on a new trial.

Immupharma has two other platforms, Ureka Sarl (Peptide) and Elro Pharma (Nucant), where the options under consideration are to license, divest or 'spin-off' the technologies.

Losses in the six months to June were £3.9mln (£4.1mln), with cash at the period-end of £2.3mln.

Quick facts: ImmuPharma PLC

Price: 13.96 GBX

AIM:IMM
Market: AIM
Market Cap: £23.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmuPharma: Analyst discusses 'impressive and potentially blockbuster' ...

The Life Sciences Division's Navid Malik gives his view on the recent recent deal ImmuPharma PLC (LON:IMM) struck with US speciality drugs group Avion Pharmaceuticals. Malik reckons its lupus candidate Lupuzor could become a 'US blockbuster' by generating over US$1bn revenues per year.

on 16/12/19

2 min read